Search

Aim: To clarify the structure of sleep disorders in cervical dystonia and assess their relationship with anxiety and depressive disorders, as well as the impact on quality of life., Material and Methods: Twenty-five patients diagnosed with cervical dystonia (CD) were examined using neurological and psychometric methods (HADS, HAM-D, TAS, SCID-II, SF-36, PSQI). Polysomnographic study was performed using a Somnolab 2 system (Weinmann, Germany)., Results: Nineteen patients (76%) from the total sample showed increases in anxiety and depression. Sleep disorders were detected in all patients diagnosed with anxiety and depressive disorders. According to questionnaires, anxiety, depression, and sleep disturbances were significantly correlated with patients' quality of life. The most common sleep disorders were intrasomic disorders (waking up during sleep) ( n =19; 76%), less common were presomnic ( n =8; 32%) and postsomnic ( n =11; 44%). Motor symptoms caused sleep disturbances only in 10 patients (40%). The specific features of sleep disorders in patients with CD detected by polysomnography are a decrease in the representation of delta-sleep, along with an increase in the phase of REM sleep, compared to physiological normal values., Conclusions: Sleep disturbances (mainly frequent waking during sleep) are widely represented in patients with cervical dystonia, are comorbid to anxiety and depressive disorders and significantly correlate with the poorer quality of life.

An aim of the study was to determine side-effects of disport, the botulinum toxin A (BTA), in the treatment of patients with spasmodic torticollis (ST) and blepharospasm (BS). More than 800 injections of BTA to patients with ST and 110 - to patients with BS have been performed for 6-years period. Side-effects are specified as follows: 1) autonomic reactions observed in women with increased anxiety and signs of autonomic dysfunction (47,5%) patients with ST), with most marked symptoms in the first injection and their further decreasing; 2) local side-effects related with errors in dose adjustment, injection technique (37,3% patients with ST and 59,5% patients with BS); 3) the smallest group of side-effects not related to the doctor's experience and adequate psychological preparation of the patient for manipulation (myasthenia-myopathia syndrome after the BTA therapy).